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Available online 26 January 2016Background: The major gene mutated in autosomal dominant polycystic kidney disease was ﬁrst identiﬁed over
20 years ago, yet its function remains poorly understood. We have used a systems-based approach to examine
the effects of acquired loss of Pkd1 in adult mouse kidney as it transitions from normal to cystic state.
Methods:Weperformed transcriptional proﬁling of a large set of male and female kidneys, along withmetabolo-
mics and lipidomics analyses of a subset of male kidneys.We also assessed the effects of a modest diet change on
cyst progression in young cysticmice. Fatty acid oxidation and glycolytic rates weremeasured in ﬁve control and
mutant pairs of epithelial cells.
Results:We ﬁnd that females have a signiﬁcantly less severe kidney phenotype and correlate this protectionwith
differences in lipid metabolism.We show that sex is a major determinant of the transcriptional proﬁle of mouse
kidneys and that some of this difference is due to genes involved in lipid metabolism. Pkd1 mutant mice have
transcriptional proﬁles consistent with changes in lipid metabolism and distinct metabolite and complex lipid
proﬁles in kidneys. We also show that cells lacking Pkd1 have an intrinsic fatty acid oxidation defect and that
manipulation of lipid content of mouse chow modiﬁes cystic disease.
Interpretation: Our results suggest PKD could be a disease of altered cellular metabolism.
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Diet1. Introduction
Autosomal Dominant Polycystic Kidney Disease (ADPKD; MIM ID's
173900, 601313, 613095) is estimated to affect almost 1/1000 and is
the most common genetic cause of end stage renal disease (Torres
et al., 2007). While advances have been made in slowing the progres-
sion of some other forms of chronic kidney disease, standard treatments
have not reduced the need for renal replacement therapy in ADPKD
(Spithoven et al., 2014). Unfortunately, several experimental interven-
tions also have recently failed to show signiﬁcant beneﬁt in slowing
the rate of functional decline (Serra et al., 2010; Walz et al., 2010;
Schrier et al., 2014; Torres et al., 2014), and the only positive study
reported very modest effects (Torres et al., 2012). These ﬁndings
suggest new treatment strategies are required.
A central dogma of molecular genetics is that discovery of the
causative geneswill lead to identiﬁcation of key pathways and potential
targets for intervention. In the case of ADPKD, the two genesmutated in
the disorder, PKD1 and PKD2, were identiﬁed almost 20 years ago and
yet their functions remain poorly understood. The PKD1 gene product,
polycystin-1 (PC1), encodes a large membrane protein that requires
the PKD2 gene product, polycystin-2 (PC2), for its trafﬁcking to thess article under the CC BY-NC-ND licprimary cilium where the two are thought to form a receptor channel
complex (Kim et al., 2014; Cai et al., 2014). What the complex senses
and what it signals remains controversial. The primary cilium has
emerged as a key player in the pathogenesis of PKD as mutations in
dozens of different genes that encode either essential ciliary compo-
nents or factors in ciliary signaling pathways result in PKD. A recent
report suggests that the relationship between the polycystin complex
and ciliary signaling is complicated, however.While ablation of primary
cilia by mutation of core ciliary components results in cysts, these same
perturbations done in the setting of Pkd1 or Pkd2 inactivation results in
signiﬁcant attenuation of cystic disease (Ma et al., 2013). These data
suggest that the polycystin complex provides a suppressive signal for
a novel, cilia-dependent growth-promoting pathway that is indepen-
dent of MAPK/ERK, mTOR, or cAMP pathways, three effector pathways
previously implicated as major drivers of cyst growth. The identities
of the growth-promoting and growth-inhibiting pathways remain
unknown.
We have taken a systems-based approach to study Pkd1 gene
function. Building on our previous work identifying markedly different
outcomes in animals with induced Pkd1 inactivation before or after
P12 and correlating this susceptibility with metabolic status (Piontek
et al., 2007; Menezes et al., 2012), we now show that female sex is
partially protective in adult-induced Pkd1 inactivation, that sex differ-
ences in metabolic status may account for this effect, and that cellsense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diet in Pkd1 mouse models, we demonstrate a positive correlation
between lipid content in mouse chow and cystic kidney disease severi-
ty. Our results therefore suggest that abnormal lipid metabolism is an
intrinsic component of PKD and an important modiﬁer of disease
progression.
2. Materials and Methods
2.1. Ethics Statement
All studies were performed using protocols approved byNIH Animal
Care and Use Committee, and mice were kept and cared in pathogen-
free animal facilities accredited by the American Association for the
Accreditation of Laboratory Animal Care and meet federal (NIH) guide-
lines for the humane and appropriate care of laboratory animal.
2.2. Animal Studies
Fifth-generation C57/BL6 Pkd1tm2Ggg (Piontek et al., 2004)micewere
crossed to the reporter mice C57/BL6 congenic B6.129S4-
Gt(ROSA)26Sortm1Sor/J (stock 003474, Jackson Laboratories) and to
C57/BL6 tamoxifen-Cre (B6.Cg-Tg(Cre/Esr1)5Amc/J mice (stock
004682), Jackson Laboratories) or Ksp-Cre B6.Cg-Tg(Cdh16-cre)91Igr/
J(stock 012237), Jackson Laboratories). For early-onset diet studies
in tamoxifen-Cre mice, nursing moms of P7 mice were induced by
one intraperitoneal injection of 0.2 mg/g tamoxifen (Sigma, T5648) in
corn oil (Sigma-Aldrich, C8267) and pups were harvested at P21. In
the Ksp-Cre line, mice were harvested at P14. In both studies, breeding
pairs and offspring were continually fed with either NIH31 or NIH37
diets for the duration of the study. For the late-onset studies, adult
mice were induced at P40 by one intraperitoneal injection of 0.2 mg/g
tamoxifen in corn oil and harvested between P86 and P210. Induced,
tamoxifen-cre negative, Pkd1tm2Ggg (referred to as Pkd1cko/cko in this
report) mice were considered controls.
2.3. Cell Lines
Kidneys from two Pkd1cko/cko animals (121112-C: male, bP12; and
94414: male, P463) were harvested, minced and digested using a
collagenase/hyaluronidase solution (Stemcell technologies, cat. no.
07912) followed by proximal or collecting/distal tubule cell enrichment
using, respectively, biotinylated Lotus tetragonolobus Lectin (LTL)
(Vector Laboratories, cat. no. B-1325) or biotinylated Dolichos biﬂorus
Agglutinin (DBA) (Vector Laboratories, ca. no. B-1035) and Cellection
Biotin Binder kit (ThermoFischer, cat. no. 11533D). Cells were immor-
talized using the large T antigen (Addgene plasmid no. 22298). Pkd1
was conditionally inactivated using cre recombinase (121112C-LTL
cells; Excellgen, cat. no. EG-1001) or viral transduction (121112-C
DBA and 94414-LTL/DBA cells) using LV-Cre (Addgene plasmid no.
12106). At the time of inactivation, a corresponding control was gener-
ated using viral transductionwith plasmid LV-Lac (Addgeneplasmid no.
12108). Pkd1 inactivation was conﬁrmed using genomic PCR and/or
reverse-transcriptase PCR (TaqMan gene expression assay, Applied
Biosystems, cat. no. 4351372, Mm00465436_g1). mCCDcl1 (mCCD)
cells were a kind gift from the Rossier lab (Gaeggeler et al., 2005).
mCCD Pkd1 knock-down cells were generated using viral transduction
with the shRNA clone TRCN0000072085 and the corresponding
pLKO.1 TRC21 control (Addgene plasmid 10,879). Cells were grown in
DMEM/F12 media (Life cat. no. 21041–025) with 2% FBS (GEMINI Bio-
Products cat. no. 100–106), 1X Insulin-Transferrin-Selenium (Thermo
Fisher Scientiﬁc, cat. no. 41400–045), 5 uM dexamethasone (SIGMA,
cat. no. D1756), 10 ng/ml EGF (SIGMA, cat. no. SRP3196), 1 nM 3,3′,5-
Triiodo-L-thyronine (SIGMA, cat. no. T6397) and 10 mM HEPES
(CORNING, cat. no. 25-060-CI).Mouse embryonic ﬁbroblasts (MEFs) were obtained from E12.5 and
E13.5 Pkd1 knockout (Pkd1tm1GGG (Bhunia et al., 2002)) and control
mice. Brieﬂy, whole embryos were minced, washed in PBS and cultured
in six-well tissue culture plate in Dulbecco's minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). A total of 6
MEF lines was used for this study: three from E13.5 mouse littermates
(2 Pkd1ko/ko and 1 Pkd1wt/wt) immortalized using large T antigen
(Addgene plasmid no. 22,298) and an additional set of three primary
(passage 2, non immortalized) E12.5 embryos (1 Pkd1ko/ko and 2
Pkd1wt/wt littermate controls).
2.4. Phenotypic Characterization
Kidneys and body weight were measured and the mean kidney/
body weight ratio was the readout for disease severity. The left kidney
was ﬁxed in 4% paraformaldehyde, centrally sectioned along the longi-
tudinal axis and processed for histology. The right kidney was snap
frozen in liquid nitrogen.
2.5. mRNA Expression Studies
Eighty mouse kidneys with induced deletion of Pkd1 at P40 were
harvested between 102 and 210 days of age (14 control females, 21
mutant females, 19 control males and 26 mutant males). Total RNA
was isolated using Trizol (Life, cat. no. 15596-018) followed by RNeasy
plus kit (Qiagen, cat. no. 74136). Further sample processing formicroar-
ray analysis was performed by the University of Chicago Genomics
Facility, Knapp Center for Biomedical Discovery, following the facility's
protocols, and hybridized to Illumina's MouseRef-8 v2.0 BeadChip
expression arrays. These data have been deposited in NCBI's Gene Ex-
pression Omnibus (Edgar et al., 2002) and are accessible through GEO
Series accession number GSE72554 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE72554).
For RT-PCR, cDNA was generated using Superscript Vilo (Life, cat.
no. 11755050) ampliﬁed with the expression assay Mm00465436_g1
(TaqMan gene expression assay, Applied Biosystems, cat. no.
4351372), normalized to Gapdh and analyzed using the delta–delta-Ct
method. Each sample was analyzed in 2 independent experiments,
each done with 3 or 4 replicates.
2.6. Statistical Analysis
Comparison of kidney/body weight (KBW) mutant male vs. female
curves was performed using generalized linear model in R (Team,
2014) and the effect size was estimated calculating Cohen's d with the
compute.es package in R. Analysis of KBW in mutants fed NIH31 or
NIH37was done using Student's t test. Real time PCR data was analyzed
ﬁtting an anova model including within subject error. Fatty acid
oxidation assay results for ﬁve technical (well) replicateswere averaged
for each cell line and genotype. The corresponding ﬁve pairs of means
were analyzed using paired t-test.
2.7. Gene Array Expression Analyses
Raw Illumina gene expression data were processed using variance
stabilization and quantile normalization with the lumi package (Du
et al., 2008; Lin et al., 2008) in R (Team, 2014), ﬁltered to include only
probes with detection call p value b0.05 in at least seven of the arrays,
followed by batch-removal using COMBAT (Johnson et al., 2007).
Same-gene probes were consolidated to a single identiﬁer keeping the
probe with highest mean value. Detection of differentially expressed
genes was performed using linear models and empirical Bayes methods
implemented in the limma package (Smyth, 2004) in R. For time course
analysis, splines and limma packages in R were used to ﬁt separate
curves in mutantmales and females for each gene, and then the param-
eters corresponding to the interaction of time and sexwere evaluated to
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mutant and control within sex were done in limma analyzing contrasts
comparing samples collected at three different time intervals. Genes
with fdr-p b 0.05 were considered differentially expressed.
The published gene expression dataset GSE25506 was downloaded
from the Gene Expression Omnibus (GEO) repository (http://www.
ncbi.nlm.nih.gov/geo/). Data were restricted to 706 mouse kidney
cortex or medulla samples and analyzed for differential expression
comparing sexual differences within anatomic region using the limma
package (Smyth, 2004) in R. Genes with fdr-p b 0.05 in both cortex
and medulla were considered differentially expressed. Comparisons
of overlap between sexual differences in the current dataset and
GSE25506 were done after restricting the datasets to only genes
expressed in both.
2.8. Network and Pathway Analysis
Weighted Gene Co-expression Network and Pathway Analysis was
performed using the WGCNA R package (Langfelder and Horvath,
2008)with soft thresholding powers selected based on the approximate
scale-free topology criterion (Zhang and Horvath, 2005), followed by
blockwise network construction, module detection, correlation with
sex/genotype and comparative network analysis to determine module
preservation. Gene ontology enrichment analysis of the identiﬁed
modules and lists of differentially expressed genes was performed in R
using GOstats (Falcon and Gentleman, 2007).
2.9. Metabolomics and Lipidomics
Kidney samples were submitted to the West Coast Metabolomics
Center, at University of California, Davis, and processed according to
the facility's protocols. Brieﬂy, lipidomics workﬂow involves sample
extraction in MTBE with addition of internal standards, followed by
ultra high pressure liquid chromatography (UHPLC) on a Waters CSH
column, interfaced to a QTOF mass spectrometer (performed using an
Agilent 1290 Inﬁnity LC system (G4220A binary pump, G4226A
autosampler, and G1316C Column Thermostat) coupled to either an
Agilent 6530 (positive ionmode) or an Agilent 6550mass spectrometer
equipped with an ion funnel (iFunnel) (negative ion mode)), with a
15min total run time. Data were collected in both positive and negative
ion mode, and analyzed using MassHunter (Agilent) to assign a unique
ID to each lipid based on its retention time and exact mass (RT_mz). For
GC-TOF, samples were prepared and analyzed using Gerstel CIS4 –with
dual MPS Injector, Agilent 6890 GC and Pegasus III TOFMS, as described
in (Fiehn et al., 2008).
Analysis was performed in R (Team, 2014). Data were log2-
transformed and centered using Pareto scaling (van den Berg et al.,
2006). Exploratory data analysis was conducted using principal compo-
nent analysis. The Shapiro–Wilk normality test was used to identify
metabolites that were normally distributed, which were then analyzed
for differential detection using linear models and empirical Bayes
methods (Smyth, 2004). Non-normally distributed metabolites were
analyzed using Wilcoxon test, followed by fdr-correction of p-values.
Metabolites with 2 fold increase/decrease and adjusted p-value b 0.05
were considered differentially expressed.
2.10. Fatty Acid Oxidation and Glycolysis Assays
A Seahorse Bioscience XF24 extracellular ﬂux analyzer and reagents
were used to infer fatty acid oxidation (FAO) and glycolysis in cells by
measuring oxygen consumption rates (OCR) and extracellular acidiﬁca-
tion rate (ECAR) following the manufacturer's instructions. Brieﬂy, for
the FAO assay, 48 h prior to the assay, 30,000 cells/well were seeded,
allowed to grow overnight and then starved for 24 h with substrate-
limited medium. The cells were re-fed with either XF Palmitate-BSA or
XF Control-BS and OCRwasmeasured at baseline and after the additionof 1.5 μM Oligomycin, 0.8 μM FCCP, 1.6uM FCCP and and 2 μM
rotennone/4 μM antimycin A. For the glycolysis assay, 60,000 cells/
well were seeded 24 h prior to the assay on a XF24 Cell culture micro-
plate in DMEM with 10% FBS. The medium was switched to glycolysis
assay medium (2 mM Glutamine in Seahorse Base Medium, pH 7.4)
and cells were incubated for 1 h in a non-CO2 37 °C incubator. OCR and
ECAR were then measured at baseline and after sequential addition of
10mMglucose, 1 μMoligomycin, and 50mM2-deoxy- D-glucose (2-DG).
3. Results
3.1. Kidney Cystic Disease Progression is Slower in Adult Female Mice
Analysis of covariance in mutant mice ﬁtting kidney/body weight
ratio (KBW) to age and using sex as a categorical factor showed that
age correlates with increased KBW (p b 0.001; n = 31 control females,
33 mutant females, 32 control males, 39 mutant males), and sex is a
modiﬁer of the rate of cyst growth (p b 0.001; Cohen's d = 1.03)
resulting in 66% to 167% increase in mutant male KBW (compared to
mutant females) (Fig. 1a), an effect not explained by differences in dele-
tion rates (Supplementary Figure S1). In contrast, liver cysts showed the
opposite trend: males have approximately 4% to 37% lower liver/body
weight ratio (LBW) (p b 0.05; Supplementary Figure S1).
3.2. Gene Expression in Kidneys is Sexually Dimorphic
Unbiased global gene expressionmicroarray data usingmultidimen-
sional scaling (MDS) showed that in eightymouse kidneys between 102
and 210 days of age (14 control females, 21 mutant females, 19 control
males and 26 mutant males) mutant and control kidneys clustered
separately and their dissimilarities correlated with worsening of the
phenotype (Fig. 1b). While this is perhaps to be expected, we were
surprised to ﬁnd that control kidneys were clustered in separate male
and female groups. In fact, roughly the same number of genes was dif-
ferentially expressed between control male and female kidneys
(3502) as between all mutant and control male samples (3721; Fig.
1c). To verify if these transcriptional sex differences were present
in other kidney datasets, we identiﬁed a large published dataset
(GSE25506 (Derry et al., 2010)) including 706 control kidney samples.
Comparing male and female kidneys in this set, we again detected
differential expression in approximately 60% of the expressed genes
(Figure S2), strongly suggesting that in mice kidney gene expression
patterns are sexually determined.
3.3. Gene Networks and Disease Mechanisms are Likely Preserved Between
Sexes
Cystogenesis could be delayed in females because different path-
ways are responsible for disease in males and females, or because path-
ways are activated to different degrees. Using WGCNA (Langfelder and
Horvath, 2008) to cluster co-expressed genes into modules and track
changes in co-expression patterns in males and females, our data
suggest networks are mostly preserved between wild type males and
females and, in fact, between all genotype/sex groups (Supplementary
Figure S3). Furthermore, it summarized genes that have distinct sex
patterns in two “meta-modules” (i.e. clusters of highly correlated
modules) which have among their signiﬁcantly enriched gene ontology
categories biological processes related to metabolic and lipid pathways
(Fig. 1d and S4; and Supplementary Table 1).
Protection in females is therefore likely derived from increased/
decreased activity of conserved functional gene clusters. Comparing
three different disease stages (pre-cystic: P100-P139; cystic: P140-
P190 and severely cystic: P190-P210) we identiﬁed hundreds of dif-
ferentially expressed genes and conﬁrmed that many differences be-
come signiﬁcant as disease progresses, few are unique to one sex,
and in cystic samples the percentage of genes that are differentially
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suggests that progression mechanisms are similar in males and fe-
males, just retarded in the latter. Gene ontology of differentiallyexpressed genes (Supplementary Table 2), in agreement with previ-
ous ﬁndings (Menezes et al., 2012; Rowe et al., 2013), suggests that
metabolic pathways are dysregulated, including lipid (p = 9.13E-
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include inﬂammation and cell locomotion/adhesion.
Our data thus showed that disease mechanisms are similar in males
and females and that lipid metabolic pathways are likely dysregulated
in mutant kidneys and different between control females and males.
We therefore hypothesized that altered lipid metabolism could be an
intrinsic component of PKD, perhaps underlying the protection seen in
females.
3.4. Metabolite and Complex Lipids Proﬁling Conﬁrm Global Metabolic
Differences in Mutant Kidneys
Metabolomics and lipidomics of 14male kidney samples (8mutant)
conﬁrmed that mutant kidneys have distinct metabolic proﬁles, partic-
ularly in more cystic stages, as shown in principal component analysis
(PCA) plots (Fig. 2, a and b). While several compounds had more than
2-fold change, only seven metabolites and one lipid (diacylglycerol
(38:6)) reached statistical signiﬁcance (Fig. 2c and Supplementary
Table 3). The small number of statistically signiﬁcant changes likely
reﬂects the mostly normal proﬁles of pre-cystic samples. In fact, even
themetaboliteswith different concentrationweremore highly correlat-
ed with KBW (mean correlation: 0.88; Fig. 2d) than with genotype
(mean correlation: 0.62), the exception being diacylglycerol (correla-
tion with KBW:−0.48; with genotype:−0.70).
3.5. Fatty Acid Oxidation is Defective in Mutant Epithelial Cells
We next tested fatty acid oxidation in vitro. We isolated and
immortalized cell lines enriched in either proximal or distal tubes
from two Pkd1 conditional mice and subsequently inactivated Pkd1
using lentiviral cre expression or cre recombinase delivery. In addition,
we used shRNA to knock-down Pkd1 in a mouse collecting duct cell line
(mCCD (Gaeggeler et al., 2005)). Measuring oxygen consumption rate
(OCR) with an extracellular ﬂux analyzer, we showed that in ﬁve differ-
ent epithelial cell lines Pkd1 inactivation resulted in lower fatty acid
oxidation (n = 5 pairs, p-value = 0.0001367; Fig. 3, a and b). Changes
in glycolysis were not observed (Fig. 3, c and d, and Supplementary
Figure S5). These results suggest that Pkd1 inactivation in kidney
epithelial cells directly contributes to the in vivo signature of lipid
metabolism dysfunction.
3.6. Lipid Metabolism is A Disease Modiﬁer
If lipid metabolism plays a role in cystogenesis, we hypothesized
that the lipid content of diets could alter disease progression. Since
breast milk fatty acid composition can be manipulated through diet
(Oosting et al., 2015), we tested the hypothesis by feeding nursing
dams two chows that differ mainly in their lipid composition (NIH31
and NIH37; supplementary ﬁles 1 and 2) to nursing moms and young
pups in two mouse models of Pkd1 inactivation: a tamoxifen-inducible
line (ER-Cre), induced at 7 days of age (P7) and harvested at P21; and
a Ksp-cre line, expressing the cre-recombinase under the control of
Ksp and resulting in epithelial deletion of Pkd1 in mid-gestation,Fig. 1. Sex is amajor determinant of disease progression and gene expression proﬁles in amouse
Pkd1 inactivation and showingmore rapid and severe kidney disease inmales (curve ﬁtted for e
for control female overlaps and is obscured by the control male line). b) Multidimensional sca
showing that sex and cystic stage are responsible for most of the difference. Each dot corres
mutant and control male and female mice showing cystic mutant male and less affected litte
and corresponding number of differentially expressed genes. d) Heatmap plot showing pattern
and each row is a gene. The colored vertical bar on the left groups genes with very similar (co
sets of correlated genes that we labeled “Meta-module 1” and “Meta-module 2” (demarcated
pattern of these genes can separate male and female kidneys. e and f) Differential expression
mutant vs. control at different age intervals in males and females. The curves show that the n
consistent with a delayed, but similar, disease process in females. f) Bar plot showing that the
age (disease severity), and is smaller in females, likely reﬂecting the delayed phenotype. In
expressed in both males and females. Each bar corresponds to genes differentially expressed oharvested at P14. The change in diet had no signiﬁcant effect on body
weight (p = 0.52 and p = 0.2, respectively; Fig. 4) and on both diets
kidneys were quite cystic. However, in both lines, decreasing the lipid
content of the diet by what seemed a trivial amount (from 7.47% fatty
acids to 5.62%) resulted in a small but statistically signiﬁcant improve-
ment (ER-Cre model: p = 0.04, Cohen's d = 0.78; n = 19(NIH31) and
14(NIH37); 95% conﬁdence interval reduction in KBW between 1.4%
and 46.4%); Ksp-Cre model: p = 0.03, Cohen's d = 0.62; n = 26
(NIH31) and 26 (NIH37); 95% conﬁdence interval reduction in KBW
between 1.1% and 19.1%; Fig. 4).
4. Discussion
While the idea that altered metabolism may be a major driver of
cellular growth iswidely appreciated in the cancer ﬁeld, this was largely
not considered for PKD until our previous network analysis of early
onset PKD (Menezes et al., 2012) and the description of a Warburg
effect in Pkd1ko/ko mouse embryonic ﬁbroblasts (Rowe et al., 2013).
The current study signiﬁcantly extends the prior work but also has
important differences. Using a systems-based approach to examine
the effects of acquired loss of Pkd1 in mouse kidney as they transition
fromnormal to cystic state, we again found that differentially expressed
genes showed enrichment for metabolic pathways and that these were
associated with global metabolic differences in cystic kidneys. Impor-
tantly, we also found that sex was an important determinant of disease
severity, that the transcriptional proﬁles of normal male and female
kidneys differed almost as much as those of normal and cystic kidneys,
and that differentially expressed gene modules were greatly enriched
for genes involved in lipid metabolism.
Though metabolic (and lipid) pathways were not the only enriched
pathways in our study, they were the common thread linking several
observations: a) female mice had less severe PKD; b) the top scoring
pathways different between normal male and female kidneys were
related to lipid metabolism; c) lipid metabolism pathways were also
different between mutant and controls. In addition, other groups have
reported slower progression of many kidney diseases in females
(reviewed in (Silbiger and Neugarten, 2008)) and that impaired fatty
acid oxidation is a component of chronic kidney disease (Kang et al.,
2015; Silbiger and Neugarten, 2008). We tested a role for lipid metabo-
lism in PKD in twoways: a) fatty acid oxidation assay using cell lines (to
differentiate between changes secondary to renal damage versus intrin-
sic defects in Pkd1ko/ko cells); and b) the effects of dietary lipid on PKD
progression in Pkd1ko/ko mice. We found that renal epithelial cells lack-
ing Pkd1 have cell autonomous defects in fatty acid oxidation. Notably,
consistent with Warner et al., but not Rowe et al., (Warner et al.,
2015; Rowe et al., 2013), we did not ﬁnd elevated lactic acid levels in
cystic kidneys nor enhanced glycolytic activity in renal epithelial cells
lacking Pkd1.
To what extent these metabolic defects contribute to PKD is still an
openquestion: Fig. 3 clearly shows lower FAO activity in eachof themu-
tant lines compared to the wild type control from which each was de-
rived, but it also shows that the range of FAO values in mutants is
similar to that of control cells. Therefore, the absolute effects resultingPKDmodel. a) Kidney to bodyweight ratios (KBW)plotted over time starting 50 days after
ach sex/genotype group using generalized linear model with gamma distribution; the line
ling (MDS) plot representing similarity in gene expression patterns between samples and
ponds to one kidney (size: correlates with KBW). c) Representative kidney histology of
rmate mutant female. Boxes delimit group comparisons using all animals in the dataset
s of gene expression between male and female control kidneys. Each column is a sample
rrelated) expression patterns into modules. These clusters can be further grouped into 2
on the right margin of the plot). The dendogram on the top shows that the expression
in cystic females mirror those in males. e) Cumulative distribution of p values comparing
umber of differentially expressed genes in females is similar to those in younger males,
number of differentially expressed genes between mutant and controls correlates with
the more severe stage, most differentially expressed genes (orange) were differentially
nly in females (red), only in males (blue), or in both (orange).
Fig. 2.Metabolic proﬁle of mouse kidneys. a and b) Principal component plots showingmetabolites and complex lipid proﬁles inmalemouse kidneys (n= 14; 8mutants and 6 controls).
The ﬁrst principal component separates genotype and KBW (purple circles: mutant; green circles: control; circle size: proportional to KBW). c) Volcano plot showing fold change and p-
value of identiﬁedmetabolites (blue) and lipids (orange) inmouse kidneys. Blue lines demarcate signiﬁcance thresholds: p b 0.05 and 2 fold change. Signiﬁcantly differentmetabolites are
marked in red and labeled. d)Heatmapplot showing relative expression of each signiﬁcantly differentmetabolite in kidney samples. The bar graph at the bottom shows the corresponding
KBW. The dendrogram at the top depicts sample distances and is labeled according to genotype (mutant: purple; control: green).
188 L.F. Menezes et al. / EBioMedicine 5 (2016) 183–192from Pkd1 loss may be quite modest. Nonetheless, our observation that
a verymodest change in the lipid composition of diet could signiﬁcantly
affect the progression of disease, in the context of the current ﬁndings,
suggests that metabolic pathways are an integral part of PKD and
supports the notion that the metabolic abnormalities observed in the
cystic kidneys result from an intrinsic defect in lipid metabolism.
There are a number of other lines of evidence that suggest that
altered cellular metabolism might be a primary factor in PKD: 1) drugs
known to have signiﬁcantmetabolic effects, like rapamycin andmetfor-
min, slowed cyst growth in Pkd1 ADPKD mouse models (Shillingford
et al., 2010; Takiar et al., 2011); 2) ciliary signaling — believed to be a
major player in PKD — plays an important role in regulating cellular
metabolismvia a number of differentmechanisms, including direct con-
trol of mitochondrial function (Boehlke et al., 2010; Oh et al., 2015; Hoff
et al., 2013); 3) mutations of several genes that encode proteins with
primary metabolic functions have been reported to cause renal cysts,including fumarate hydratase (OMIM 150800) (Lehtonen et al., 2006;
Adam et al., 2011) and, in glutaric acidemia type II (OMIM 231680),
genes encoding proteins involved in electron transfer in the mitochon-
drial respiratory chain (ETFA, ETFB, ETFDH (Böhm et al., 1982; Wilson
et al., 1989); 4) ﬁnally, a recent report describing that Fat (ft), an
atypical cadherin, long-studied as a prototypical member of the planar
cell polarity pathway (PCP) (Sing et al., 2014), undergoes proteolytic
cleavage to release a soluble 68 kDa fragment that is imported into
mitochondria where it binds directly to and stabilizes the activity of
NADH dehydrogenase ubiquionone ﬂavoprotein 2, a core component
of complex I activity. As defects in planar cell polarity (PCP) can
cause PKD, usually believed as secondary to disrupted mitotic spindle
orientation or convergent-extension processes during development
(Fischer et al., 2006; Karner et al., 2009), this ﬁnding is particularly
interesting and may provide another link between cilia, metabolism
and PKD.
189L.F. Menezes et al. / EBioMedicine 5 (2016) 183–192The observation that sex is an important determinant of disease se-
verity in orthologous models of ADPKD has not been previously report-
ed, but it is not surprising given that human studies suggest that malesFig. 3. Fatty acid oxidation, but not glycolysis, is defective in kidney epithelial cell lines. a and
epithelial cell lines using palmitate as a substrate. a) OCR proﬁle (line colors: different cell line
A: 1.5 μM oligomycin, B: 0.8 μM FCCP, C: 0.8 μM FCCP, D: 2 μM rotennone/4 μM antimycin A).
points are the rates measured between vertical lines C and D of the OCR proﬁle (shape int
showing extracellular acidiﬁcation rate (ECAR) as a readout for glyocolysis. c) ECAR as a pe
sequential addition of 10 mM glucose, 1.5 μM oligomycin, 1.5 μM oligomycin and 50 mM 2-de
in the c panels, calculated as the increase over baseline after the addition of oligomycin (shapewith autosomal dominant PKD have worse renal cystic disease but less
severe liver cystic disease (Reed et al., 2008; Cnossen andDrenth, 2014).
The interplay between sexual dimorphism and PKD severity likelyb) Fatty acid oxidation assay measuring oxygen consumption rate (OCR) in ﬁve kidney
pairs, dashed line: mutant (i.e. lacking Pkd1), full line: control; vertical line: injection of
b) Violin plot of maximum respiration rate measurements of different cell line pairs. Data
erior color: genotype). Paired t test: n = 5 pairs, p-value = 0.0001367. c and d) Plots
rcentage of baseline in two epithelial cell lines. The vertical dashed lines represent the
oxy-D-glucose (2-DG). d) Violin plots showing the glycolytic capacity of the experiment
interior color: genotype). Paired t test: n = 2 pairs, p-value = 0.691.
Fig. 4. Diet lipid content is positively correlated with severity of cystic kidney disease. a) In both tamoxifen-inducible (ER-CRE) and Ksp-Cre induced mouse model, kidney/body weight
(KBW) in increased in animals fed NIH37 diet, which has higher lipid content. b) Body weight is not statistically different between the two diets.
190 L.F. Menezes et al. / EBioMedicine 5 (2016) 183–192occurs onmultiple levels, as previous studies have identiﬁed inﬂamma-
tory pathways and cAMP signaling as both important progression
factors in PKD (Torres et al., 2004, 2012; Torres and Harris, 2014;
Menon et al., 2011; Klawitter et al., 2013; Karihaloo et al., 2011)
and subject to sex effects (Grimble, 2002; Barton and Prossnitz, 2015;
Davis et al., 2014; Auger, 2003; Abrahám and Herbison, 2005;
Liu et al., 2011; Juul et al., 2014). Our data suggest that sexual
differences in fatty acid metabolism may be another important
disease-modulating factor.
Our ﬁndings also may have broader implications for other forms of
renal injury as male sex is associated with accelerated progression in
many kidney diseases (Silbiger and Neugarten, 2008). Gene expression
analysis of samples of patients with chronic kidney disease (CKD) was
reported enriched for genes involved in inﬂammatory and metabolic
pathways, particularly fatty acid oxidation (FAO), a pattern somewhat
similar to the ﬁndings presented here (Kang et al., 2015). Similarly,
transgenic mice overexpressing in proximal tubules PPARalpha, a
known regulator of FAO, seemed to have reduced morphological
damage after ischemic injury (Li et al., 2013). These effects are postulat-
ed to involvemodulation of ﬁbrotic responses. If and how such cascades
relate to the metabolomics of PKD, if microcystic changes commonly
found in CKD contribute to itsmetabolic component andwhat is unique
or shared in the metabolic trigger or response of different kidney
diseases remain to be studied.
These data have a number of other important implications. Our diet
studies provide conﬁrmation that in an orthologous PKDmodel diet can
modify disease and suggest the possibility that diet could be a modiﬁ-
able risk factor in humans. It should be noted that our study is unusual
in that the diet manipulation was trivial: while many high-fat diet ma-
nipulations aim for fat as the primary source of energy, NIH-31 (~5.6%
fat) and NIH-37 (~7.5%) can be used interchangeably inmouse colonies,
the latter being sometimes preferred for lactating moms. That we can
detect a difference should be a reminder that research conducted
asynchronously or in different animal facilities within the same institu-
tion could not be directly comparable if diet is not standardized. It also
suggests that clinical studies might be improved by stratiﬁcation
according to diet and/or metabolic parameters.This study also suggests two important new lines for future investi-
gation: how loss of Pkd1 results in a cell autonomous fatty acid oxidation
defect and, more broadly, how altered cellular metabolism leads to
dysregulation of tubular diameter and planar cell polarity. While meta-
bolic reprogrammingmay contribute to the increased proliferation seen
in some forms of PKD, hyperproliferation is not a universal feature of all
forms of cystic disease. One intriguing speculation is that the abnormal-
ities we have identiﬁed are associated with altered lipid biosynthetic
pathways, the latter playing important roles in regulating cellularmem-
brane properties and hence cellular structure and function (Holthuis
and Menon, 2014).
In conclusion, we have shown a signiﬁcant sexual difference in
PKD progression in this mouse model, identiﬁed altered lipid
metabolism as a possible underlying cause and conﬁrmed that
PKD has an intrinsic dysfunction in fatty acid oxidation. We there-
fore suggest that PKD could be a disease of altered cellular metabo-
lism, a model that nicely links a number of otherwise disconnected
ﬁndings in a common process. These results have important impli-
cations for how one should model and study the disease and
opens new avenues to understand pathogenesis and ameliorate
disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.01.027.Authors's Contributions
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